Drugs / JP-1366
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT07265466 | Nov 2025 → Mar 2026 overdue | — | Onconic Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07181538 | Feb 2025 | — | Onconic Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05712681 | Mar → May 2023 | — | Onconic Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05814809 | Sep → Oct 2022 | — | Onconic Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05181124 | Mar 2021 | active peptic ulcer disease | Onconic Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05194046 | Nov 2020 → Jan 2021 | Helicobacter pylori infectious disease | Onconic Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03383042 | Dec 2017 → Nov 2018 | active peptic ulcer disease | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04282954 | Nov 2019 → Oct 2020 | gastroesophageal reflux disease | Onconic Therapeutics Inc. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07160790 | Sep 2025 → Jun 2026 overdue | gastroesophageal reflux disease | Onconic Therapeutics Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06439563 | Oct 2024 → Aug 2027 expected | peptic ulcer disease | Onconic Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05448001 | Sep 2022 → Jul 2024 | gastric ulcer | Onconic Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05443984 | Jan 2022 → Jan 2023 | esophagitis | Onconic Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JP-1366 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05814809 ↗ |
| Known as | Zastaprazan | “Zastaprazan (JP-1366) is a novel potassium-competitive acid blocker with a fast onset and prolonged duration.” PMID 41540828 ↗ Jan 2026 |
| Route | Oral | “JP-1366 Oral Administration” NCT03383042 ↗ |